Cargando…
Integrated safety analysis of treatment‐emergent eczematous reactions in patients with moderate‐to‐severe psoriasis treated with ixekizumab, etanercept and ustekinumab
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518506/ https://www.ncbi.nlm.nih.gov/pubmed/34076896 http://dx.doi.org/10.1111/bjd.20527 |
| _version_ | 1784584239853862912 |
|---|---|
| author | Brunner, P.M. Conrad, C. Vender, R. Grond, S. Schuster, C. Patel, H. Xu, W. Carrascosa Carrillo, J.M. |
| author_facet | Brunner, P.M. Conrad, C. Vender, R. Grond, S. Schuster, C. Patel, H. Xu, W. Carrascosa Carrillo, J.M. |
| author_sort | Brunner, P.M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8518506 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85185062021-10-21 Integrated safety analysis of treatment‐emergent eczematous reactions in patients with moderate‐to‐severe psoriasis treated with ixekizumab, etanercept and ustekinumab Brunner, P.M. Conrad, C. Vender, R. Grond, S. Schuster, C. Patel, H. Xu, W. Carrascosa Carrillo, J.M. Br J Dermatol Correspondence John Wiley and Sons Inc. 2021-08-10 2021-10 /pmc/articles/PMC8518506/ /pubmed/34076896 http://dx.doi.org/10.1111/bjd.20527 Text en © 2021 Eli Lilly and Company. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Correspondence Brunner, P.M. Conrad, C. Vender, R. Grond, S. Schuster, C. Patel, H. Xu, W. Carrascosa Carrillo, J.M. Integrated safety analysis of treatment‐emergent eczematous reactions in patients with moderate‐to‐severe psoriasis treated with ixekizumab, etanercept and ustekinumab |
| title | Integrated safety analysis of treatment‐emergent eczematous reactions in patients with moderate‐to‐severe psoriasis treated with ixekizumab, etanercept and ustekinumab |
| title_full | Integrated safety analysis of treatment‐emergent eczematous reactions in patients with moderate‐to‐severe psoriasis treated with ixekizumab, etanercept and ustekinumab |
| title_fullStr | Integrated safety analysis of treatment‐emergent eczematous reactions in patients with moderate‐to‐severe psoriasis treated with ixekizumab, etanercept and ustekinumab |
| title_full_unstemmed | Integrated safety analysis of treatment‐emergent eczematous reactions in patients with moderate‐to‐severe psoriasis treated with ixekizumab, etanercept and ustekinumab |
| title_short | Integrated safety analysis of treatment‐emergent eczematous reactions in patients with moderate‐to‐severe psoriasis treated with ixekizumab, etanercept and ustekinumab |
| title_sort | integrated safety analysis of treatment‐emergent eczematous reactions in patients with moderate‐to‐severe psoriasis treated with ixekizumab, etanercept and ustekinumab |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518506/ https://www.ncbi.nlm.nih.gov/pubmed/34076896 http://dx.doi.org/10.1111/bjd.20527 |
| work_keys_str_mv | AT brunnerpm integratedsafetyanalysisoftreatmentemergenteczematousreactionsinpatientswithmoderatetoseverepsoriasistreatedwithixekizumabetanerceptandustekinumab AT conradc integratedsafetyanalysisoftreatmentemergenteczematousreactionsinpatientswithmoderatetoseverepsoriasistreatedwithixekizumabetanerceptandustekinumab AT venderr integratedsafetyanalysisoftreatmentemergenteczematousreactionsinpatientswithmoderatetoseverepsoriasistreatedwithixekizumabetanerceptandustekinumab AT gronds integratedsafetyanalysisoftreatmentemergenteczematousreactionsinpatientswithmoderatetoseverepsoriasistreatedwithixekizumabetanerceptandustekinumab AT schusterc integratedsafetyanalysisoftreatmentemergenteczematousreactionsinpatientswithmoderatetoseverepsoriasistreatedwithixekizumabetanerceptandustekinumab AT patelh integratedsafetyanalysisoftreatmentemergenteczematousreactionsinpatientswithmoderatetoseverepsoriasistreatedwithixekizumabetanerceptandustekinumab AT xuw integratedsafetyanalysisoftreatmentemergenteczematousreactionsinpatientswithmoderatetoseverepsoriasistreatedwithixekizumabetanerceptandustekinumab AT carrascosacarrillojm integratedsafetyanalysisoftreatmentemergenteczematousreactionsinpatientswithmoderatetoseverepsoriasistreatedwithixekizumabetanerceptandustekinumab |